semaglutide and cardiovascular outcomes in patients with type 2 diabetes Oral Semaglutide and Cardiovascular Outcomes

Learn about the benefits, including cost savings and assured stock.

Genetically-predicted GLP1R expression (the target of GLP-1 RAs) showed an inverse association with background [odds ratio (OR)=0.83, 95% CI, 0.710.97] and severe nonproliferative DR (OR=0.72, 95% CI, 0.530.98), and a non-significant association with overall (OR=0.97, 95% CI, 0.921.03) and proliferative DR (OR=0.98, 95% CI, 0.911.05)

Small and mid-sized businesses that are members of the PEO will now have easier access to high-quality, affordable health benefits

Physician-supervised GLP-1 therapy

Discover the side effects of GLP-1 medications and learn how to manage them